POTENTIAL FOR COMBINED THERAPY WITH 348U87, A RIBONUCLEOTIDE REDUCTASE INHIBITOR, AND ACYCLOVIR AS TREATMENT FOR ACYCLOVIR-RESISTANT HERPES-SIMPLEX VIRUS-INFECTION

被引：0

作者：

SAFRIN, S

SCHACKER, T

DELEHANTY, J

HILL, E

COREY, L

机构：

[1] UNIV CALIF SAN FRANCISCO,DEPT MED EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143

[2] UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195

[3] UNIV WASHINGTON,DEPT LAB MED,SEATTLE,WA 98195

[4] UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195

[5] BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709

来源：

JOURNAL OF MEDICAL VIROLOGY | 1993年

关键词：

TOPICAL; 348U87; HIV INFECTION; HSV INFECTION;

D O I：

暂无

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Inhibitors of the ribonucleotide reductase of herpes simplex viruses (HSV) potentiate the activity of acyclovir in vitro and in animal studies. In addition, the combination of the ribonucleotide reductase inhibitor 348U87 and acyclovir has synergistic therapeutic effects against infections in mice due to thymidine kinase-deficient, thymidine kinase-altered, and DNA polymerase mutants of HSV. We performed a pilot study of topical combination therapy with 348U87 (3%) and acyclovir (5%) cream for acyclovir-resistant, anogenital HSV infections in ten human immunodeficiency virus (HIV)-infected patients. Our results, with lack of complete reepitheliazation of lesions in all patients and poor virologic response, suggest that this therapy is unlikely to be useful for this indication. (C) 1993 Wiley-Liss, Inc.

引用

页码：146 / 149

页数：4

共 17 条

[1] RIBONUCLEOTIDE REDUCTASE ENCODED BY HERPES-SIMPLEX VIRUS IS A DETERMINANT OF THE PATHOGENICITY OF THE VIRUS IN MICE AND A VALID ANTIVIRAL TARGET [J].